Varying Effects of Body Mass Index and Mortality in Different Risk Groups.

[1]  S. Yusuf,et al.  Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes. , 2017, The American journal of cardiology.

[2]  A. Pandey,et al.  The Interaction of Cardiorespiratory Fitness With Obesity and the Obesity Paradox in Cardiovascular Disease. , 2017, Progress in cardiovascular diseases.

[3]  J. Schwalm,et al.  Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis , 2017, Acta cardiologica.

[4]  V. Beral,et al.  Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents , 2016, The Lancet.

[5]  S. Yusuf,et al.  Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[6]  F. Gao,et al.  Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis , 2015, Heart.

[7]  Sunil V. Rao,et al.  Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.

[8]  Robert F Kushner,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[9]  F. Hu,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[10]  Connie M. Rhee,et al.  Why cachexia kills: examining the causality of poor outcomes in wasting conditions , 2013, Journal of cachexia, sarcopenia and muscle.

[11]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[12]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[13]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[14]  M. Whooley,et al.  Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. , 2012, Atherosclerosis.

[15]  S. Yusuf,et al.  Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study , 2011, European journal of preventive cardiology.

[16]  Sunil V. Rao,et al.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial , 2011, The Lancet.

[17]  Yikyung Park,et al.  Body-mass index and mortality among 1.46 million white adults. , 2010, The New England journal of medicine.

[18]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[19]  Sunil V. Rao,et al.  Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. , 2010, JAMA.

[20]  S. Yusuf,et al.  Early versus delayed invasive intervention in acute coronary syndromes. , 2009, The New England journal of medicine.

[21]  N. Nguyen,et al.  Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. , 2008, Journal of the American College of Surgeons.

[22]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[23]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[24]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[25]  V. Montori,et al.  Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies , 2006, The Lancet.

[26]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[27]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[28]  S. Yusuf,et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.

[29]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[30]  S. Coppack,et al.  Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[31]  R. Ferrari,et al.  The role of TNF in cardiovascular disease. , 1999, Pharmacological research.

[32]  K Kataoka,et al.  [Indices of obesity derived from body weight and height]. , 1995, Nihon rinsho. Japanese journal of clinical medicine.